Novartis contends Roche unjustly enriched itself with $210 mln in fees -lawsuit – Reuters

REUTERS/Arnd WiegmannLawsuit originates from 2005 patent licensing pactNovartis looks for $210 mln in alleged overpaymentRoche has long owned rewarding patents required by rival biotechsZURICH, June 29 (Reuters) – Novartis AG (NOVN.S) desires Roche Holding AG (ROG.S) to return $210 million after implicating its Swiss competitor of incorrectly swiping charges from a 16-year-old patent licensing arrangement, according to a suit in U.S. District Court.The dispute, launched by Novartis in a California state court but recently shifted to a federal court, originates from a 2005 offer requiring U.S.-based Chiron Corp to pay to Roches U.S. Genentech system for use of its intellectual property.In 2006, Novartis purchased Chiron, a maker of biological drugs and vaccines, and continued making the payments to Roche as it developed items like swelling drug Ilaris, with income of roughly $900 million annual, and psoriasis drug Cosentyx, Novartiss existing leading seller at around $4 billion annual.” Genentech knew or should have been mindful that Novartis had actually paid too much … to Genentech throughout the regard to the Agreement,” Novartis legal agents wrote.” Genentech has in fact been unjustly boosted at Novartiss expense,” Novartis attorneys wrote.Reporting by John Miller
Customizing by Mark Potter and Bill BerkrotOur Standards: The Thomson Reuters Trust Principles.